Vertex has set the price of Orkambi at £105,000 per-patient per-year, and turned down an offer of £500m over four years from NHS England for the use of the drug and a second therapy that was in development, Symkevi.Since talks broke down Vertex has withdrawn Symkevi from the UK drug approval process, meaning it will not be available to any NHS patients.
Campaigners point out that Orkambi was developed in part with funding from a cystic fibrosis charity and the National Institute of Health in the US. "We think that is a clear demonstration that the NHS is undervaluing the benefits these medicines can have for people living with cystic fibrosis."
Because they hold the country and patients to ransom £104.000 pounds a year for 1 patient While getting government funding for research Then rip off pricing Just like Pfizer on the insulin £84 million fine Have they paid it yet
So the government allow cigarette sales still and fund all those smoking-related illnesses under the NHS and don't start me on food manufacturers and high carb (i.e. sugar) foods and fund all those increasing Type 2 Diabetic illnesses BUT NOT THIS?